Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Montijo – page 53

673 clinical trials in Montijo, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Montijo at a glance
673
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

673 trials in Montijo

Open in trial search

Monkeypox

Not recruiting

Study on Tecovirimat for Treating Monkeypox in Patients with Confirmed Infection

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Tecovirimat
  • Sponsor:Universitair Medisch Centrum Utrecht

Study of Pembrolizumab as Additional Treatment for Patients with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma After Surgery and Radiation

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Not recruiting

Study of Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Selexipag and Bosentan for Children with Pulmonary Arterial Hypertension

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Bosentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Oesophageal carcinoma

Not recruiting

Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Hypertonic bladder

Not recruiting

Study on Overactive Bladder Treatment for Women Using Clostridium Botulinum Neurotoxin Type A and Vibe System

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:IncobotulinumtoxinA
  • Sponsor:Vensica Medical Ltd.

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Macular oedema

Not recruiting

Study on the Effects of RO7200220 for Adults and Children with Uveitic Macular Edema

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Vamikibart
  • Sponsor:F. Hoffmann-La Roche AG

Netherton's syndrome

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Acute kidney injury

Not recruiting

Study on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Hidradenitis

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Montijo

What the registry says about research in the country

01 Cardiovascular Diseases

Montijo hosts a focused research effort on cardiovascular diseases, with two active recruiting trials at a single site led by a local investigator.

  • Evaluation of zilebesiran in patients with uncontrolled hypertension and established or high‑risk cardiovascular disease
  • Assessment of the antibody combination REGN7508 and REGN9933 for preventing ischemic stroke and systemic embolism in atrial fibrillation patients
  • Investigation of major bleeding risk associated with the REGN antibody therapy
  • Inclusion of participants with atrial fibrillation, established cardiovascular disease, high cardiovascular risk and hypertension

These studies aim to improve outcomes by testing novel therapies and safety profiles, positioning Montijo as a niche hub for cardiovascular innovation in Portugal.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.